Literature DB >> 1726707

Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.

L Prin1, J Plumas, V Gruart, S Loiseau, D Aldebert, J C Ameisen, A Vermersch, P Fenaux, O Bletry, M Capron.   

Abstract

We report here the presence of very high serum levels of the soluble interleukin-2 receptor (sIL-2R) in patients with blood hypereosinophilia with or without detectable markers of malignancy or signs of visceral involvement. The highest sIL-2R levels were observed in 16 eosinophilic patients with T-cell lymphoma (3,440 to 79,500 U/mL). Elevated levels of sIL-2R were also present (1,330 to 22,500 U/mL) in sera from 38 patients with the hypereosinophilic syndrome (HES) without detectable T-cell lymphoma. In this group of patients, the highest levels were noted in the patients with the malignant form of HES. Significantly lower levels were measured in sera of patients with hypereosinophilia associated with parasitic diseases, allergic disorders, or other miscellaneous diseases. Elevated serum sIL-2R levels were not closely paralleled by changes in the number of CD25-positive peripheral blood mononuclear cells as assessed by flow cytometric analysis. However, expression of IL-2R messenger RNA was detected in blood mononuclear cells collected from HES patients. In eight eosinophilic patients with T-cell lymphoma, the serum sIL-2R levels were significantly correlated with the eosinophil counts, and with the total number of blood hypodense eosinophils. alpha-Interferon (alpha-IFN) therapy resulted in both a dramatic clinical improvement and a rapid decrease in sIL-2R levels and blood hypereosinophilia. Similar beneficial effects of alpha-IFN were noted in patients with malignant HES who lacked a detectable T-cell lymphoma. Our data indicate that HES is associated with elevated serum IL-2R levels. The highest levels were observed in the most severe forms of HES with hematologic markers of malignancy or evident visceral involvement. Serum levels of sIL-2R might represent a useful indicator for the management of HES patients. In addition, the respective changes of sIL-2R and blood eosinophilia might reflect distinct processes of mononuclear cell activation affecting the eosinophil lineage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726707

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome.

Authors:  P Khoury; P Zagallo; C Talar-Williams; C S Santos; E Dinerman; N C Holland; A D Klion
Journal:  Allergy       Date:  2012-07-09       Impact factor: 13.146

2.  Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene.

Authors:  Keisuke Kataoka; Koji Izutsu; Sumimasa Nagai; Akira Hangaishi; Toru Motokura; Tsuyoshi Takahashi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

3.  Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer.

Authors:  Hiroki Kato; Katsura Kohata; Joji Yamamoto; Satoshi Ichikawa; Mika Watanabe; Kenichi Ishizawa; Ryo Ichinohasama; Hideo Harigae
Journal:  Int J Hematol       Date:  2010-02-05       Impact factor: 2.490

4.  Marked and persistent eosinophilia in the absence of clinical manifestations.

Authors:  Yun-Yun K Chen; Paneez Khoury; JeanAnne M Ware; Nicole C Holland-Thomas; Jennifer L Stoddard; Shakuntala Gurprasad; Amy J Waldner; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2013-08-26       Impact factor: 10.793

5.  Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

Authors:  L Schandené; G F Del Prete; E Cogan; P Stordeur; A Crusiaux; B Kennes; S Romagnani; M Goldman
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 6.  Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome.

Authors:  K Tajima; T Katagiri
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.